Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
The company is advancing AAV gene therapies for DMD and FA, prioritizing these programs with novel constructs and delivery platforms. Key FDA meetings and data readouts are expected in the next two quarters, with a strong cash position supporting operations into 2028.Based on Solid Biosciences Inc…
The company is advancing gene therapies for Duchenne muscular dystrophy and Friedreich's ataxia, with key FDA meetings and data readouts expected in the next two quarters. Novel delivery platforms and simplified immunosuppression protocols differentiate their programs, and a strong cash position su…
Gene therapy programs for DMD and FA are advancing, with high demand and robust biomarker strategies supporting clinical development. Novel capsid technology enables superior biodistribution and safety, while streamlined FA procedures and global expansion plans position the company for significant…